Floatz logo

gi-102

Progressive Astrocytoma, IDH-Mutant, Grade 4

Mayo ClinicPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Progressive Astrocytoma, IDH-Mutant, Grade 4 cohort.

Asset / SponsorPhaseRating
Nivolumab
Andrew P. Groves
Phase 2B
Safusidenib
Nuvation Bio Inc.
Phase 3B
Pembrolizumab
Mayo Clinic
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Ribociclib
St. Jude Children's Research Hospital
Phase 1CC

View all 15 →

Same molecule, other indications

gi-102 is also rated in:

glioblastomaDormant
CCC
Indicative ·
53 / 100
View asset →
IDH-wildtype glioblastomaDormant
CCC
Indicative ·
53 / 100
View asset →
astrocytoma (excluding glioblastoma)Dormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →